Literature DB >> 20197648

Improved synthesis of ADAM10 inhibitor GI254023X.

Nicole Hoettecke1, Andreas Ludwig, Sabine Foro, Boris Schmidt.   

Abstract

BACKGROUND: The metalloproteinases ADAM10 and ADAM17 are involved in various diseases: neurodegeneration, cancer and inflammation.
OBJECTIVE: The inhibition of these proteases is a promising target in the treatment of inflammation and cancer. METHODS AND
RESULTS: In this study, we present an improved synthesis of the ADAM10 reference inhibitor GI254023X with a higher overall yield, enhanced detection ability and increased acid stability, providing easier handling.
CONCLUSION: This upscaled synthesis, free of diastereomeric intermediates, ensures single-batch identity, thus warranting its reproducibility in further biological investigations. 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197648     DOI: 10.1159/000267865

Source DB:  PubMed          Journal:  Neurodegener Dis        ISSN: 1660-2854            Impact factor:   2.977


  11 in total

1.  Statins stimulate the production of a soluble form of the receptor for advanced glycation end products.

Authors:  Patricia Quade-Lyssy; Anna Maria Kanarek; Markus Baiersdörfer; Rolf Postina; Elzbieta Kojro
Journal:  J Lipid Res       Date:  2013-08-21       Impact factor: 5.922

2.  ADAM10 mediates vascular injury induced by Staphylococcus aureus α-hemolysin.

Authors:  Michael E Powers; Hwan Keun Kim; Yang Wang; Juliane Bubeck Wardenburg
Journal:  J Infect Dis       Date:  2012-04-02       Impact factor: 5.226

3.  The Role of Shed PrPc in the Neuropathogenesis of HIV Infection.

Authors:  Bezawit W Megra; Eliseo A Eugenin; Joan W Berman
Journal:  J Immunol       Date:  2017-05-22       Impact factor: 5.422

4.  Ablation of amyloid precursor protein increases insulin-degrading enzyme levels and activity in brain and peripheral tissues.

Authors:  Joshua A Kulas; Whitney F Franklin; Nicholas A Smith; Gunjan D Manocha; Kendra L Puig; Kumi Nagamoto-Combs; Rachel D Hendrix; Giulio Taglialatela; Steven W Barger; Colin K Combs
Journal:  Am J Physiol Endocrinol Metab       Date:  2018-11-13       Impact factor: 4.310

5.  Inhibiting pathologically active ADAM10 rescues synaptic and cognitive decline in Huntington's disease.

Authors:  Elena Vezzoli; Ilaria Caron; Francesca Talpo; Dario Besusso; Paola Conforti; Elisa Battaglia; Elisa Sogne; Andrea Falqui; Lara Petricca; Margherita Verani; Paola Martufi; Andrea Caricasole; Alberto Bresciani; Ottavia Cecchetti; Pia Rivetti di Val Cervo; Giulio Sancini; Olaf Riess; Hoa Nguyen; Lisa Seipold; Paul Saftig; Gerardo Biella; Elena Cattaneo; Chiara Zuccato
Journal:  J Clin Invest       Date:  2019-05-06       Impact factor: 14.808

6.  Mapping and functional characterization of murine kidney injury molecule-1 proteolytic cleavage site.

Authors:  Saranga Sriranganathan; Elena Tutunea-Fatan; Alina Abbasi; Lakshman Gunaratnam
Journal:  Mol Cell Biochem       Date:  2020-11-19       Impact factor: 3.396

7.  An evolutionary recent neuroepithelial cell adhesion function of huntingtin implicates ADAM10-Ncadherin.

Authors:  Valentina Lo Sardo; Chiara Zuccato; Germano Gaudenzi; Barbara Vitali; Catarina Ramos; Marzia Tartari; Michael A Myre; James A Walker; Anna Pistocchi; Luciano Conti; Marta Valenza; Binia Drung; Boris Schmidt; James Gusella; Scott Zeitlin; Franco Cotelli; Elena Cattaneo
Journal:  Nat Neurosci       Date:  2012-05       Impact factor: 24.884

8.  Soluble CD23 controls IgE synthesis and homeostasis in human B cells.

Authors:  Alison M Cooper; Philip S Hobson; Mark R Jutton; Michael W Kao; Binia Drung; Boris Schmidt; David J Fear; Andrew J Beavil; James M McDonnell; Brian J Sutton; Hannah J Gould
Journal:  J Immunol       Date:  2012-03-05       Impact factor: 5.422

9.  ADAM10-Mediated Ectodomain Shedding Is an Essential Driver of Podocyte Damage.

Authors:  Marlies Sachs; Sebastian Wetzel; Julia Reichelt; Wiebke Sachs; Lisa Schebsdat; Stephanie Zielinski; Lisa Seipold; Lukas Heintz; Stephan A Müller; Oliver Kretz; Maja Lindenmeyer; Thorsten Wiech; Tobias B Huber; Renate Lüllmann-Rauch; Stefan F Lichtenthaler; Paul Saftig; Catherine Meyer-Schwesinger
Journal:  J Am Soc Nephrol       Date:  2021-03-30       Impact factor: 14.978

10.  Glioblastoma recurrence correlates with NLGN3 levels.

Authors:  Rui Liu; Xing-Ping Qin; Yang Zhuang; Ya Zhang; Hua-Bao Liao; Jun-Chun Tang; Meng-Xian Pan; Fei-Fei Zeng; Yang Lei; Rui-Xue Lei; Shu Wang; An-Chun Liu; Juan Chen; Zhi-Feng Zhang; Dan Zhao; Song-Lin Wu; Ren-Zhong Liu; Ze-Fen Wang; Qi Wan
Journal:  Cancer Med       Date:  2018-05-18       Impact factor: 4.452

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.